Federal prosecutors placed the approximately $268 million Michael McMillan wound-care case within a seven-case Northern District of Texas enforcement campaign involving thirteen defendants and more than $365 million in alleged fraudulent billing across several taxpayer-supported healthcare programs.
WASHINGTON, DC — The federal indictment of Las Vegas businessman Michael McMillan stands at the center of one of the Northern District of Texas’s most substantial healthcare fraud crackdowns, with prosecutors attributing approximately $268 million in allegedly false claims to his wound-care distribution operation.
The regional campaign announced on June 23, 2026, encompasses seven separate criminal cases, thirteen defendants, and more than $365 million in allegedly fraudulent billing submitted to federally funded programs and other insurers, according to the United States Attorney’s Office.
Among those cases, the McMillan prosecution carries the largest individually announced billing figure, giving the Protectus investigation unusual financial weight while placing skin-substitute reimbursement practices beside allegations involving laboratories, neurological testing, hospice services, COVID-19 kits, and medical equipment.
That comparative scale does not establish guilt, prove loss, or determine punishment, because an indictment contains allegations rather than evidence and prosecutors must establish every element of each charged offense beyond a reasonable doubt through admissible, defendant-specific proof.
McMillan remains presumed innocent, and the regional announcement cannot substitute for the transaction records, clinical documents, communications, witness testimony, expert analysis, and legal rulings that will ultimately shape his individual prosecution before a federal court.
One Case Dominates the Announced Regional Benchmark
The Northern District of Texas announcement describing the coordinated crackdown attributes approximately $268 million in allegedly false claims to McMillan and more than $365 million in collective fraudulent billing to the seven regional prosecutions.
Because prosecutors described the regional number as exceeding $365 million rather than providing a final, audited total, responsible comparisons should not convert McMillan’s allegation into an exact percentage or assume every separately published case figure represents entirely distinct, nonoverlapping billing.
Even with that limitation, approximately $268 million plainly makes the McMillan matter the largest case by the individually announced claim amount within the regional group, substantially exceeding the figures publicly associated with each of the other six prosecutions.
The scale also makes the case a prominent local contribution to the nationwide takedown, although McMillan lived in Las Vegas and allegedly controlled Nevada companies, illustrating how federal healthcare investigations often span corporate locations, provider networks, payment systems, and judicial districts.
Seven Cases Present Several Alleged Fraud Models
The Northern District’s package did not describe one unified conspiracy among all thirteen defendants; instead, it assembled seven independent prosecutions involving different companies, services, beneficiaries, payment arrangements, charging documents, investigators, alleged losses, and evidentiary records.
Those matters collectively addressed laboratory testing, transcranial magnetic stimulation, electroencephalography, hospice enrollment, COVID-19 test kits, skin-substitute wound products, and durable medical equipment, demonstrating the breadth of conduct that federal authorities place under the healthcare fraud enforcement umbrella.
Some allegations concern services never provided or products beneficiaries allegedly neither needed nor requested, while others center upon medical necessity, kickbacks, pricing disclosures, beneficiary recruitment, concealed remuneration, or transactions involving property allegedly derived from criminal activity.
Combining those prosecutions in one public announcement increases visibility and signals coordinated enforcement, but jurors deciding any particular case must disregard unrelated accusations and evaluate only evidence properly admitted against the defendants before them.
Laboratory Testing Allegations Reached Approximately $65 Million
Federal prosecutors charged Devin Jack Brodman by information with conspiracy to defraud the United States and paying and receiving kickbacks concerning claims submitted through two North Texas laboratories for testing services, including genetic tests allegedly ineligible for reimbursement.
The government says Neva Diagnostics and Areahou Diagnostics billed Medicare about $65 million and received about $43 million, while Brodman allegedly concealed fraudulent claims tied to laboratory orders procured through unlawful kickbacks and bribes.
An information ordinarily reflects a prosecutor-filed accusation rather than a grand-jury indictment, and the differing procedural vehicle does not eliminate the government’s burden to prove guilt or obtain a valid plea supported by an adequate factual basis.
The laboratory matter remains financially significant within the regional crackdown, but its allegations, witnesses, billing rules, business relationships, and potential defenses differ from the skin-substitute pricing and provider-payment arrangements attributed to McMillan and Protectus.
TRICARE Testing Case Allegedly Involved Nearly $27 Million
Kevin Darnell Curry was charged by indictment over an alleged scheme involving transcranial magnetic stimulation treatments billed to TRICARE, with prosecutors claiming approximately $26.9 million in false submissions and approximately $17.1 million in resulting payments.
The government alleges the treatments were not provided, were misrepresented, were medically unnecessary, were induced through illegal remuneration, or were otherwise ineligible, while authorities also reported seizing about $200,000 in assets, including cash and a gold Tesla Cybertruck.
That prosecution highlights the regional campaign’s focus on military healthcare funding, while the McMillan indictment allegedly reaches Medicare, TRICARE, and CHAMPVA through wound-care product claims generated by providers across a broader commercial distribution network.
Although both matters include kickback and criminally derived property allegations, similarity in statutory language does not establish a shared plan, common participants, identical evidence, or comparable culpability between defendants facing independently developed federal cases.
Neurological Testing Charges Added More Than $25 Million
Physicians Olubayo Idowu and James Lou Carlisle Jr., along with nurse practitioner Vaughn Anthony Brozek, were charged in a superseding indictment involving more than $25 million in allegedly fraudulent electroencephalography claims submitted to Medicare and other benefit programs.
Prosecutors allege the defendants accepted kickbacks and bribes for medically unnecessary patient testing between 2020 and at least 2023, presenting another theory in which financial remuneration allegedly displaced independent clinical judgment and program eligibility requirements.
Medical necessity evidence in that prosecution may depend upon patient histories, ordering records, symptoms, interpretations, provider communications, applicable coverage standards, and expert testimony, rather than the acquisition-price representations and product invoices emphasized in McMillan’s wound-care case.
Placing both cases within the same takedown underscores a common enforcement concern about financially influenced care, but it cannot erase the specialized medical and reimbursement questions that prosecutors must prove independently for each charged service.
Hospice Case Focused on Eligibility and Unprovided Care
Catherine Nkeiru Maduka, identified as the owner and chief executive of Saint Catherine’s Hospice, was charged with conspiracy and healthcare fraud involving more than $3.1 million in allegedly false Medicare claims for hospice services.
The indictment alleges that Maduka recruited patients who were not eligible for hospice benefits and billed Medicare for services never provided, a factual theory centered upon terminal-illness qualifications, enrollment practices, clinical documentation, and actual delivery of covered care.
Although its published dollar figure is considerably smaller than McMillan’s, the hospice matter may still involve profound patient consequences because improper enrollment and nonexistent services can affect medically fragile beneficiaries, caregivers, providers, and finite program resources.
Dollar comparisons therefore illuminate enforcement scale without measuring human impact, evidentiary strength, individual intent, litigation complexity, or sentencing exposure, all of which depend upon the charged conduct and facts ultimately established within each separate proceeding.
COVID-19 Test-Kit Allegations Exceeded $73 Million
Four defendants were charged through a superseding indictment with conspiring to violate the federal Anti-Kickback Statute in connection with more than $73 million in allegedly fraudulent Medicare claims submitted for COVID-19 test kits distributed through laboratory businesses.
Prosecutors say beneficiary information was provided to laboratory owners who billed for kits sent without requests, sometimes using information associated with deceased beneficiaries, before allegedly returning portions of reimbursement through cash and financial transactions designed to conceal kickbacks.
The case represents the second-largest individually described claim figure within the Northern District announcement, yet it remains far below the approximately $268 million attributed to McMillan’s alleged skin-substitute reimbursement and provider-profit system.
An NBC 5 Dallas-Fort Worth report covering the seven North Texas cases emphasized allegations targeting elderly beneficiaries and military-related programs, while highlighting conspicuous assets associated with several prosecutions, including a Cybertruck and private aircraft.
Durable Medical Equipment Case Alleged Approximately $2.3 Million
Neel Vivek Paithankar, identified as the owner of VMP Health Care, was charged with conspiracy and healthcare fraud concerning approximately $2.3 million in Medicare claims for durable medical equipment prosecutors describe as medically unnecessary.
The government alleges telemarketers posed as Medicare representatives while offering free equipment, after which VMP shipped products to beneficiaries who allegedly did not need or want them, generating approximately 3,700 claims and about $1.2 million in payments.
That prosecution illustrates how beneficiary solicitation and unwanted equipment can create fraud exposure even when individual items carry much lower reimbursement values than the expensive skin-substitute products described within the McMillan indictment.
Its inclusion also shows that federal authorities assess recruitment methods, beneficiary consent, medical need, product delivery, billing volume, and reimbursement results together, rather than limiting regional enforcement priorities exclusively to the largest headline amounts.
Protectus Allegations Drive McMillan’s Regional Prominence
Prosecutors allege McMillan owned and controlled six Nevada entities operating collectively under the Protectus name, which distributed skin-substitute products and recruited physicians, podiatrists, nurse practitioners, and other providers between approximately May 2019 and February 2026.
Under the alleged arrangement, providers obtained products without paying upfront, owed Protectus nothing when government programs denied reimbursement, and paid the distributor only after successful claims, leaving practices with approximately thirty to forty percent of collected reimbursements.
The indictment characterizes those retained amounts as illegal kickbacks concealed through rebate or discount terminology, while alleging that Protectus received approximately $174 million after government programs paid approximately $268 million on challenged skin-substitute claims.
Prosecutors further contend that the claims contained inflated acquisition-price information, including entries that allegedly failed to disclose the products’ effective economic cost after accounting for contingent invoices, provider retention, rebates, discounts, and reimbursement-linked adjustments.
The defense can dispute whether those arrangements constituted unlawful inducements, whether pricing instructions were sufficiently clear, whether providers controlled final submissions, whether products delivered legitimate value, and whether McMillan knowingly joined either charged conspiracy.
Regional Jurisdiction Reflects the Reach of Federal Programs
McMillan’s residence and corporate base outside Texas do not prevent prosecution within the Northern District when alleged claims, providers, transactions, communications, beneficiaries, conspiratorial acts, or investigative connections establish venue under governing federal rules and constitutional requirements.
Healthcare payment systems routinely cross state lines because distributors, manufacturers, clinicians, billing companies, beneficiaries, contractors, banks, and federal administrators may operate in different jurisdictions while participating in one reimbursement sequence tied to a single medical product.
That geographic complexity can expand investigative reach while generating defense questions concerning venue, personal participation, corporate separateness, document custody, witness availability, search authority, and whether conduct occurring elsewhere properly supports counts filed in North Texas.
The regional label consequently describes the prosecuting district and coordinated enforcement action, not a claim that every alleged McMillan transaction, company, provider, patient, asset, or reimbursement decision occurred physically within the Northern District of Texas.
Multiple Agencies Built the Enforcement Campaign
The Federal Bureau of Investigation’s Dallas Field Office, Health and Human Services Office of Inspector General, Defense Criminal Investigative Service, and Department of Veterans Affairs Office of Inspector General investigated the McMillan matter, according to prosecutors.
Other regional cases involved overlapping combinations of those agencies and the Texas Attorney General’s Medicaid Fraud Control Unit, reflecting how claim data, beneficiary interviews, clinical records, financial tracing, and program expertise frequently require interagency cooperation.
Investigators can compare billing patterns across providers, identify sudden utilization changes, trace reimbursements through corporate accounts, examine communications surrounding product selection, and test whether claim fields align with contracts, invoices, discounts, rebates, and actual economic obligations.
Data analytics can reveal patterns and prioritize investigative resources, but statistical anomalies remain starting points rather than convictions because lawful clinical growth, unusual patient populations, coverage changes, documentation practices, and business expansion may also produce conspicuous billing results.
The National Takedown Amplified Local Cases
The North Texas prosecutions formed part of the 2026 National Health Care Fraud Takedown, which announced charges against 455 defendants, including ninety doctors and other licensed medical professionals, concerning more than $6.5 billion in alleged false claims nationwide.
Federal officials described activity across fifty-six districts and forty-five states and territories, participation by fifty state Medicaid Fraud Control Units, administrative action against thousands of providers, and seizures exceeding $182 million in cash and other assets.
Within that sweeping national narrative, the Northern District contributed a comparatively concentrated set of seven cases, while McMillan’s approximately $268 million allegation supplied a substantial portion of the district’s prominently advertised enforcement footprint.
National scale can encourage deterrence and demonstrate coordination, yet trial courts must guard against guilt by association because unrelated defendants, alleged schemes, patient harms, or seized assets cannot establish McMillan’s intent or conduct.
A Large Claim Total Is Not Automatically a Proven Loss
The approximately $268 million figure concerns payments prosecutors characterize as resulting from fraudulent claims, but later loss calculations may examine medical necessity, legitimate product value, pricing representations, kickback consequences, claim eligibility, repayments, denials, credits, and evidentiary limitations.
Forfeiture, restitution, program loss, corporate receipts, provider remuneration, representative commissions, seized property, and billed amounts are legally distinct measures, even when public announcements group several figures into one memorable account of alleged misconduct.
Courts may also distinguish between amounts submitted and amounts paid, between gross proceeds and net gain, and between property traceable to sustained offenses and assets reachable only through substitute-property provisions after specified conditions are proven.
Those distinctions matter especially in a prosecution advertised as one of the region’s largest, because impressive aggregate figures can influence public perception long before adversarial testing determines which claims, transactions, theories, and losses withstand scrutiny.
Seized Assets Add Visibility Without Establishing Guilt
Authorities reported seizing assets valued at approximately $35 million in connection with McMillan’s case, while the indictment separately identifies real estate, luxury vehicles, and a private aircraft within transaction counts and requested forfeiture allegations.
Publicly listed property should not automatically be described as permanently forfeited or included within the announced seizure total, because pretrial restraint, charged monetary transactions, specific-asset forfeiture notices, and final ownership judgments represent different procedural stages.
McMillan can challenge tracing, ownership, valuation, commingling, legitimate funding sources, probable cause, and statutory coverage, while spouses, lenders, companies, co-owners, or other third parties may assert independently protected interests in disputed property.
Luxury purchases can make complicated financial allegations understandable for jurors, but expensive homes, automobiles, or aircraft do not prove healthcare fraud unless prosecutors connect particular transactions with criminally derived property and establish McMillan’s required knowledge.
Patients and Taxpayers Remain Central to the Crackdown
The seven cases allegedly affected Medicare beneficiaries, military families, veterans, hospice patients, and equipment recipients, populations whose healthcare decisions may carry exceptional consequences when treatment, enrollment, testing, or product selection becomes influenced by undisclosed financial incentives.
Improper claims can divert finite public resources, increase program costs, distort clinical markets, and weaken confidence in legitimate providers, while unnecessary treatment or failure to deliver promised care can expose individual patients to avoidable risk.
Enforcement must nevertheless avoid stigmatizing appropriate wound care, neurological testing, hospice services, laboratory medicine, or durable medical equipment, because these services can provide substantial benefits when clinically justified, accurately documented, and lawfully billed.
The government must therefore prove misconduct without asking jurors to infer criminality merely from reimbursement size, business profitability, uncommon utilization, sophisticated sales practices, or participation in medical sectors under heightened investigative scrutiny.
Compliance Lessons Reach Beyond the Defendants
Healthcare distributors and practices should scrutinize arrangements where providers pay nothing before treatment, owe nothing after claim denial, retain fixed percentages of successful reimbursement, or receive product terms that change according to government payment outcomes.
Compliance teams should test whether acquisition-price disclosures reflect final economic cost, clinical selection remains independent, commissions reward claim success, representatives emphasize provider profit, and billing assistance accurately communicates discounts, rebates, credits, and contingent obligations.
Organizations should preserve medical charts, orders, invoices, contracts, reimbursement notices, claim forms, commission reports, training materials, electronic messages, bank records, and corrective actions because ordinary documents may later establish knowledge, control, consistency, reliance, or good-faith compliance.
Independent claim sampling can identify repeated pricing entries, unusual utilization, concentrated products, beneficiary complaints, mismatched quantities, denial patterns, rapid geographic expansion, and compensation formulas before questionable practices become embedded across a larger provider network.
Reputation Effects Begin Before Courtroom Testing
A coordinated federal announcement can quickly place a defendant’s name beside enormous claim figures, vulnerable patients, luxury property, and national enforcement statistics, shaping search results before discovery, motions, testimony, verdicts, and appeals establish final facts.
Individuals or companies facing that imbalance may need disciplined crisis public-relations management that distinguishes allegations from adjudicated conduct, protects confidential information, corrects verifiable inaccuracies, coordinates authorized statements, and avoids emotional commentary that could harm litigation strategy.
Longer-term reputation-rebuilding strategies can document verified compliance reforms, leadership decisions, procedural developments, independent audits, and final court outcomes without concealing material facts or inaccurately presenting unresolved allegations as proven guilt or complete exoneration.
McMillan, Protectus entities, clinicians, sales representatives, employees, beneficiaries, creditors, and property claimants may occupy sharply different factual positions, making tailored communications essential whenever a collective response could imply shared culpability or disclose protected information.
What Happens Next in Federal Court
Pretrial proceedings may address claim data, provider agreements, pricing guidance, acquisition-cost fields, commission structures, corporate records, search procedures, account restraints, property valuations, electronic communications, witness credibility, expert methods, venue, and financial tracing across multiple jurisdictions.
Prosecutors will seek to show that Protectus used reimbursement-linked provider profits and misleading price information to generate fraudulent claims, while the defense will attempt to separate lawful distribution practices from independent clinical and billing decisions.
Expert testimony may become especially important when jurors evaluate skin-substitute standards, program reimbursement rules, commercial discounts, contingent invoices, statistical patterns, legitimate product value, kickback restrictions, and whether disputed representations could have influenced payment decisions.
Any eventual sentence, restitution order, or forfeiture judgment would depend upon sustained counts, proven loss, McMillan’s role, criminal history, legitimate value, recovered property, victim evidence, advisory guidelines, statutory limits, and individualized judicial discretion.
No final outcome can responsibly be predicted from the regional takedown announcement, because discovery, evidentiary rulings, witness cooperation, plea discussions, factual stipulations, trial testimony, jury findings, post-trial motions, and appeals may materially reshape the case.
Until jurors return verdicts or another lawful resolution concludes the prosecution, Michael McMillan remains presumed innocent, every Protectus allegation remains subject to adversarial testing, and the government must prove each charged offense beyond a reasonable doubt.
